Search
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of ...
Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2C8 InhibitorsCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of DB00448, which is ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesTirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsRomidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown eff...
Categories: N-Calcium Channel Receptor AntagonistsIsavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the br...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InducersDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigationalDesvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of venlafaxine. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) c...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsPitavastatin
go.drugbank.com/drugs/DB08860ApprovedInvestigationalPitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates